drugset
drugset / Trial / NCT05743777

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

NCT05743777 ↗

Phase 2 Withdrawn Canadian Cancer Trials Group NuBiyota · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The usual approach for patients who are not in a study is treatment with pembrolizumab, a type of immunotherapy drug. Immunotherapy works by allowing the immune system to detect your cancer and reactivate the immune response. This may help to slow down the growth of cancer and may cause cancer cells to die.

Timeline

Start
2023-05-12
Primary completion
2023-05-12
Completion
2023-05-12

Outcome

Outcome not reported

Stopped (Business): “Company withdrew financial support”

Drugs

EvaluationDrugModalityDoseRoute
Subject MET-4 Other / unclassified 1.5 g —
Subject Pembrolizumab Monoclonal antibody 400 mg Intravenous

Indications

head and neck squamous cell carcinoma